Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with ovarian cancer (specifically epithelial, serous, or clear cell type), confirmed by a tissue or cell sample, and who are currently receiving their first round of chemotherapy (the study drug should start alongside the first or second chemotherapy cycle), whether given before surgery, after surgery, or for advanced disease.
• People aged 18 years or older.
• People with a life expectancy of more than 6 months.
• People who are generally able to carry out daily activities with little or no limitation (as assessed by their doctor using a standard health scale).
• People whose blood, liver, and kidney tests fall within acceptable ranges, including healthy enough platelet counts, blood clotting times, liver enzyme levels, and kidney function (the trial site can confirm the specific values required).
• People who are willing and able to use reliable contraception (hormonal, barrier methods, or abstinence) throughout the study — this applies to both women who could become pregnant and men. Anyone who becomes pregnant during the study must inform their treating doctor immediately.
• People who are able to understand the study information and are willing to sign a consent form.

Who may not be able to join:

• People who have had a blood clot in a vein (such as a deep vein thrombosis or pulmonary embolism) within the last 2 years, unless it was related to a central line and anticoagulation treatment has since been completed.
• People who are actively bleeding or who are considered at high risk of bleeding (for example, those with a known active stomach or intestinal ulcer).
• People who have had a serious bleeding episode requiring hospitalisation or a blood transfusion within the last 24 months, outside of a surgical context.
• People with an inherited condition that affects blood clotting (familial bleeding disorder).
• People with a known diagnosis of disseminated intravascular coagulation (a serious blood clotting disorder) (confirm with trial site).
• People who are currently taking blood-thinning (anticoagulant) medication.
• People who take daily aspirin, clopidogrel (Plavix), cilostazol (Pletal), or aspirin-dipyridamole (Aggrenox), or who regularly take high doses of anti-inflammatory pain relievers such as ibuprofen above 800 mg per day — the treating doctor will assess this on a case-by-case basis.
• People with other serious uncontrolled health conditions, such as an active infection, heart failure, unstable chest pain, heart rhythm problems, or mental health or personal circumstances that could make it difficult to follow the study requirements.
• People who are known to have an intolerance or allergy to isoquercetin, niacin, or ascorbic acid (vitamin C), including those with a condition called G6PD deficiency.
• People with known cancer that has spread to the brain.
• People who are currently pregnant or breastfeeding, as the effects of the study drug on unborn babies or nursing infants are not known. Breastfeeding would need to be stopped if a person begins treatment with the study drug.

Important: Always verify eligibility with the trial site directly before applying.